Humatrope Direct Connect

Humatrope DirectConnect

Humatrope DirectConnect offers a patient support program designed to help patients start and continue Humatrope while they still have time to grow. Patient support includes a dedicated Case Manager, Benefits Investigation, Prior Authorization Support, Humatrope FastTrack Program (if eligible*), Appeals Support, Humatrope Co-pay Card (if eligible†), HumatroPen® Training, and Reauthorization Support.

*Eligibility required. Humatrope appeals support and FastTrack are subject to terms and conditions.

†Eligibility Terms and Conditions

DirectConnect Portal

Now you can access one central source for important information and updates about your patients with Humatrope prescriptions.

Visit the portal

Statement of Medical Necessity and Authorization Forms

When you need them, the following resources are available to download or print as needed.

Your patients also have the option to submit their Patient Authorization electronically. Learn more about electronic Patient Authorization.

Co-pay Program

Help eligible patients save on their Humatrope prescription

To help eligible patients save on their prescription

As the cost of healthcare continues to change, so do your patients’ financial needs. That’s why the Humatrope Co-pay Card is frontloaded with an annual $2400 balance that’s available from the start, so your patients can use as much as they need to cover their monthly Humatrope costs. See terms and conditions below for eligibility requirements.*

If you have any questions about the Humatrope Co-pay Program, please call 1-866-923-1953, Monday through Friday 8 AM - 8 PM Eastern Time.

This offer may be terminated, rescinded, revoked, or amended by Lilly USA, LLC at any time without notice.

Patient co-pay page


*$2400 annual cap subject to usual and customary pharmacy charges. Offer expires 12/31/2018. This offer is invalid for patients without commercial insurance coverage or those whose prescription claims are eligible to be reimbursed, in whole or in part, by Medicare Part D, Medicaid, TRICARE or any other state or federal program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation required. Subject to additional terms and conditions, which can be found here.

To see what steps your eligible patients can take to download or activate a Co-pay Card, visit the patient co-pay page.

Humatrope patient support for healthcare professionals

Stimulation Test Guide

This booklet is designed to help patients and caregivers understand what the test is, why it's needed, and what to expect before, during, and after the test.

Download brochure

Ready, Set, Grow Brochure

Parents can use this brochure to help their children know more about growth, factors that affect it or interfere with it, and ways to measure it over time. It also includes tips on helping children with short stature, and a section to write down notes for their doctor.

Download brochure
Ready Set Grow book

Helpful links

The links below are provided to direct you to other internet resources that you may find useful and informative.

Indications and Important Safety Information
INDICATION

Humatrope® (somatropin for injection) is indicated for the treatment of pediatric patients who have short stature or growth failure as a result of:

  • Growth hormone (GH) deficiency.
  • Turner syndrome.
  • Idiopathic short stature, defined by height standard deviation score ≤-2.25, associated with growth rates unlikely to result in normal adult height, in whom other causes of short stature have been excluded.
  • SHOX deficiency.
  • Small for gestational age birth, and fail to show catch-up growth by 2 to 4 years of age.

Humatrope is indicated for the replacement of endogenous GH in adults with GH deficiency, either:

  • Adult-onset, as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
  • Childhood-onset. Patients treated for GH deficiency in childhood who have closed epiphyses should be reevaluated to determine if they should continue growth hormone.

CONTRAINDICATIONS

  • Acute Critical Illness: Somatropin should not be used to treat patients with acute critical illness from complications after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure.
  • Prader-Willi Syndrome in Children: Somatropin should not be used in pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. Humatrope is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome.
  • Active Malignancy: Somatropin is contraindicated in patients with any evidence of active malignancy.
  • Hypersensitivity: Humatrope is contraindicated in patients with a known hypersensitivity to somatropin or the supplied diluent.
  • Diabetic Retinopathy or Closed Epiphyses: Somatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy. It should not be used for growth promotion in pediatric patients with closed epiphyses.

WARNINGS AND PRECAUTIONS
  • Acute Critical Illness: Increased mortality in patients with acute critical illness from complications after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic amounts of somatropin.
  • Prader-Willi Syndrome in Children: There have been reports of fatalities after starting therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Patients with Prader-Willi syndrome should be evaluated for signs of upper airway obstruction and sleep apnea before initiation of treatment with somatropin.
  • Neoplasms: An increased risk of a second neoplasm has been reported for childhood cancer survivors treated with somatropin for GH deficiency that developed following radiation to the brain/head. Intracranial tumors, in particular meningiomas, were the most common of these second neoplasms. In adults, it is unknown whether there is any relationship between somatropin replacement therapy and CNS tumor recurrence. Monitor for progression or recurrence in all patients receiving somatropin therapy who have a history of GH deficiency secondary to an intracranial neoplasm.
  • Glucose Intolerance and Diabetes Mellitus: Previously undiagnosed impaired glucose tolerance and overt diabetes mellitus may be unmasked during somatropin treatment. New-onset type 2 diabetes mellitus has been reported. Blood glucose concentrations should be monitored periodically in all patients taking somatropin, especially in those with risk factors for diabetes mellitus and those with pre-existing type 1 or type 2 diabetes mellitus or impaired glucose tolerance. The dose of antihyperglycemic drugs may require adjustment when somatropin treatment is instituted.
  • Intracranial Hypertension: Intracranial hypertension with papilledema, visual changes, headache, nausea, and/or vomiting have been reported in a small number of patients treated with somatropin. If papilledema is observed by funduscopy during treatment with somatropin, treatment should be stopped and the patient’s condition should be reassessed before treatment is resumed.
  • Severe Hypersensitivity: Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with use of somatropin products.
  • Fluid Retention: Transient and dose-dependent fluid retention during somatropin replacement in adults may occur frequently.
  • Hypoadrenalism: Patients receiving somatropin therapy who have or are at risk for pituitary hormone deficiencies may be at risk for reduced serum cortisol levels and/or unmasking of central hypoadrenalism. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of somatropin treatment.
  • Hypothyroidism: Patients treated with somatropin should have periodic thyroid function tests, and thyroid hormone replacement therapy should be initiated or adjusted in cases of unmasked or worsening hypothyroidism.
  • Slipped Capital Femoral Epiphysis in Pediatric Patients: Slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders and in patients undergoing rapid growth. Any pediatric patient with the onset of a limp or complaints of hip or knee pain during somatropin therapy should be carefully evaluated.
  • Progression of Scoliosis in Pediatric Patients: Progression of scoliosis can occur in patients who experience rapid growth. Patients with a history of scoliosis who are treated with somatropin should be monitored for progression of scoliosis. Somatropin has not been shown to increase the occurrence of scoliosis.
  • Pancreatitis: Cases of pancreatitis have been reported rarely in children and adults receiving somatropin. Pancreatitis should be considered in any somatropin-treated patient, especially a child, who develops abdominal pain.
  • Lipoatrophy: Tissue atrophy may result when somatropin is administrated subcutaneously at the same site over a long period of time. This can be avoided by rotating the injection site.
ADVERSE REACTIONS

  • Common adverse reactions reported in adult and pediatric patients taking somatropin include injection site reactions, hypersensitivity to the diluent, and hypothyroidism. Additional common adverse reactions in adults include edema, arthralgia, myalgia, carpal tunnel syndrome, paresthesias, and hyperglycemia.

ADDITIONAL INFORMATION

Click to access Full Prescribing Information, Patient Information-Cartridge, and Patient Information-Vial.

See Full Pen User Manual that accompanies the HumatroPen® 6 mg, 12 mg, and 24 mg.

Humatrope is a registered trademark owned or licensed by Eli Lilly & Company, its subsidiaries, or affiliates.
HG HCP ISI 13JAN2017

Are you a US Healthcare provider?

The information contained in this section of humatrope.com is intended for US Healthcare providers. Please confirm below.

Are you a US Healthcare provider?

The information contained in this section of humatrope.com is intended for US Healthcare providers. Please confirm below.

You are now leaving humatrope.com.

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

Click “Continue” to leave site or “Return to humatrope.com” to close this window and return to humatrope.com.

By using the Humatrope Co-Pay Card (“Card”), you attest that you meet the eligibility criteria and will comply with the Terms and Conditions described below: Offer void where prohibited by law. This offer is invalid for patients whose prescription claims for Humatrope are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DOD, VA, TRICARE/CHAMPUS, or any State Patient or Pharmaceutical Assistance Program. If you live in Massachusetts, the Card expires on the earlier of: (i) the expiration date of this Card (12/31/2018) or (ii) the date an AB rated generic equivalent for Humatrope becomes available. Available only in the US and Puerto Rico for residents of the US and Puerto Rico. If you live in California, the card expires on the earlier of the (i) the expiration date of this card (12/31/2018) or (ii) the date an FDA approved therapeutically equivalent for Humatrope or over the counter product with the same active ingredients becomes available. By accepting this offer, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you should notify your insurance carrier of your redemption of this Card. This offer is not valid with any other program, discount, incentive, or similar offer involving Humatrope. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit this card. This offer may be terminated, rescinded, revoked, or amended by Lilly USA, LLC at any time without notice. This Card is not health insurance. This Card expires on 12/31/2018.

Call Humatrope DirectConnect at 1-84Humatrope (1-844-862-8767),
Monday through Friday 8 AM - 8 PM Eastern time